Clinical Trial Search

Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants

Primary: Prepulse Inhibition — -.19; -.31 proportion of change in OEMGR response

Primary: Simple Reaction Time With the Dominant Hand — 258.7; 254.7; 252.6; 252.3 millisecond (ms) — p=0.76

Primary: Percentage of Patients Treated With Anticoagulation Initially Started at the 12 Month — 89.5; 89.5 percentage of participants — p=0.8496

Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 185; 39 Participants

Primary: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf) — 104; 141; 83.5; 244 µM*hr

Primary: Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A — 1; 1; 1; 3 Participants

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using…

Primary: Number of Participants Who Received HIV Testing — 21; 22; 16 Participants

Primary: Number of Participants by Their Sociodemographic Characteristics: Smoking Habit — 207; 23; 1844; 7 Participants — p=0.000

Primary: Maximum Concentration (Cmax) for Serum Testosterone and Testosterone Enanthate — 773.7; 1487.0; 49.25; 267.33 ng/dL

Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms

Primary: Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 — 20.2; 6.7; 21.1 Hairs — p=<.001

Primary: Early Clinical Assessment of Balance (ECAB) — 79.4; 61.1; 38.0; 23.0 units on a scale

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to…